201 related articles for article (PubMed ID: 35294622)
1. Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus.
Beaulieu Q; Zhang D; Melki I; Baudouin V; Goldwirst L; Woillard JB; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2022 Jun; 78(6):1003-1010. PubMed ID: 35294622
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
[TBL] [Abstract][Full Text] [Related]
3. Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm.
Koloskoff K; Benito S; Chambon L; Dayan F; Marquet P; Jacqz-Aigrain E; Woillard JB
Eur J Clin Pharmacol; 2024 Jan; 80(1):83-92. PubMed ID: 37897528
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.
Woillard JB; Bader-Meunier B; Salomon R; Ranchin B; Decramer S; Fischbach M; Berard E; Guigonis V; Harambat J; Dunand O; Tenenbaum J; Marquet P; Saint-Marcoux F
Br J Clin Pharmacol; 2014 Oct; 78(4):867-76. PubMed ID: 24697955
[TBL] [Abstract][Full Text] [Related]
6. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome.
Benz MR; Ehren R; Kleinert D; Müller C; Gellermann J; Fehrenbach H; Schmidt H; Weber LT
Ther Drug Monit; 2019 Dec; 41(6):696-702. PubMed ID: 31425441
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
[TBL] [Abstract][Full Text] [Related]
8. Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients.
Xiang H; Zhou H; Zhang J; Sun Y; Wang Y; Han Y; Cai J
Front Pharmacol; 2021; 12():652333. PubMed ID: 33912061
[No Abstract] [Full Text] [Related]
9. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
Saint-Marcoux F; Guigonis V; Decramer S; Gandia P; Ranchin B; Parant F; Bessenay L; Libert F; Harambat J; Bouchet S; Broux F; Compagnon P; Marquet P
Pharmacol Res; 2011 May; 63(5):423-31. PubMed ID: 21272643
[TBL] [Abstract][Full Text] [Related]
10. Exposure levels of mycophenolic acid are associated with comorbidities in children with systemic lupus erythematosus.
Ye Q; Wang G; Lu J; Huang Y; Zhang J; Zhu L; Zhu Y; Lan J; Li Z; Liu Y; Xu H; Li Z
Lupus; 2021 Oct; 30(11):1808-1818. PubMed ID: 34304630
[TBL] [Abstract][Full Text] [Related]
11. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
[TBL] [Abstract][Full Text] [Related]
12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
13. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of mycophenolic acid in pediatric patients with juvenile dermatomyositis and optimization of limited sampling strategy.
Wang G; Ye Q; Huang Y; Lu J; Xu H; Li Z
Xenobiotica; 2021 Feb; 51(2):167-176. PubMed ID: 32903096
[TBL] [Abstract][Full Text] [Related]
16. A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation.
Gota V; Purohit V; Gurjar M; Nayak L; Punatar S; Gokarn A; Bonda A; Bagal B; Vora CS; Patil A; Nookala M; Khattry N
Cell Transplant; 2020; 29():963689720912925. PubMed ID: 32495641
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
18. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
de Winter BC; Monchaud C; Prémaud A; Pison C; Kessler R; Reynaud-Gaubert M; Dromer C; Stern M; Guillemain R; Knoop C; Estenne M; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Jan; 51(1):29-39. PubMed ID: 22054177
[TBL] [Abstract][Full Text] [Related]
19. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.
Djabarouti S; Breilh D; Duffau P; Lazaro E; Greib C; Caubet O; Saux MC; Pellegrin JL; Viallard JF
Arthritis Res Ther; 2010; 12(6):R217. PubMed ID: 21176194
[TBL] [Abstract][Full Text] [Related]
20. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
